

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number  
**WO 2004/084893 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/439**,  
31/52, 31/4015, A61P 35/00

(21) International Application Number:  
PCT/SE2004/000452

(22) International Filing Date: 24 March 2004 (24.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0300812-5 24 March 2003 (24.03.2003) SE  
60/456,525 24 March 2003 (24.03.2003) US

(71) Applicant (for all designated States except US): **APREA AB** [SE/SE]; c/o Karolinska Innovations AB, Fogdevreten 2B, S-171 77 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STRÖMBLAD, Staffan** [SE/SE]; Fullerstavägen 46 A, S-141 44 Huddinge (SE). **BAO, Wenije** [CN/SE]; Diagnosvägen 3C, S-141 53 Huddinge (SE). **SELIVANOVA, Galina** [RU/SE]; Hagalundsgatan 44, S-169 64 Solna (SE). **ISSAEVA, Natalia** [RU/SE]; Röntgenvägen 1/410, S-141 52 Huddinge (SE).

(74) Agent: **DR. LUDWIG BRANN PATENTBYRÅ AB**; P.O. BOX 171 92, Maria Skolgata 83, S-104 62 Stockholm (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL USE OF 1-AZABICYCLO[2.2.2]OCTANES AND A METHOD OF TESTING COMPOUNDS FOR THE ABILITY OF ACTIVATING INACTIVE WT P53

(57) Abstract: The present invention relates to the use of 1-azabicyclo[2.2.2]octanes, capable of transferring wild type p53 from an inactive and non-functional conformation into an active conformation, for the preparation of a pharmaceutical compositions for use in treating medical compositions wherein wt p53 exists in an inactive state defined herein, especially malignant melanoma and conditions involving undesired angiogenesis. The invention also relates to methods of *in vivo* and *in vitro* testing of compounds for the above-mentioned ability, wherein inactive wt p53 is monitored or detected.



WO 2004/084893 A1

Pharmaceutical use of 1'-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53.

5    **Field of the invention**

The present invention relates to the use of certain compounds, capable of transferring wild type p53 from an inactive and non-functional conformation into its active conformation, for the preparation of a pharmaceutical composition for use in treating medical conditions wherein wt p53 exists in an inactive state defined herein, and especially malignant melanoma. The invention also relates to a method of testing of compounds for the above-mentioned ability, wherein the level of inactive wt p53 is monitored. The method can be carried out both *in vitro* and *in vivo*.

15   **Background art**


Although the tumour suppressor protein p53 is mutated in most human tumours, wild type (wt) p53 is dominant in malignant melanoma (Hollstein et al., *Science*, 253: 49-53, (1991); Sparrow et al., *Melanoma Res.* 1995. 5: 93-100 (1995); and Hartmann et al., *Int J cancer*, 67: 313-317, (1996)) Petitclerc et al., *Cancer Res*, 59: 2724-2730 (1999)) found Mab LM609, a function-blocking monoclonal antibody directed to  $\alpha_v\beta_3$  integrin, to block M21 melanoma growth by inducing tumour apoptosis.

25   Malignant melanoma are typically refractory to apoptosis induction by chemical drugs or radioactivity.

**Summary of invention**

30   The present inventors have found certain compounds to be capable of inducing apoptosis in malignant melanoma cells, which compounds are defined in claim 1 as having a structure according to the formula (I)

5



15 wherein

n is 0, 1 or 2;

R<sup>1</sup> and R<sup>2</sup> are the same or different and are selected from -H, -CH<sub>2</sub>-R<sup>5</sup>, -CH<sub>2</sub>-O-R<sup>5</sup>,  
 -CH<sub>2</sub>-S-R<sup>5</sup>, -CH<sub>2</sub>-NH-R<sup>5</sup>, -CO-O-R<sup>5</sup>, -CO-NH-R<sup>5</sup>, -CH<sub>2</sub>-NH-CO-R<sup>5</sup>,  
 -CH<sub>2</sub>-O-CO-R<sup>5</sup>, -CH<sub>2</sub>-NH-CO-NHR<sup>5</sup>, -CH<sub>2</sub>-NH-CO-OR<sup>5</sup>, -CH<sub>2</sub>-NH-CS-NHR<sup>5</sup> and

20 -CH<sub>2</sub>-O-CO-NHR<sup>5</sup>;or R<sup>1</sup> and R<sup>2</sup> are together =CH<sub>2</sub>;

R<sup>3</sup> and R<sup>4</sup> are the same or different and are selected from H, -OH, -SH, -NH<sub>2</sub>, -NHR<sup>5</sup>  
 and

-O-CO-C<sub>6</sub>H<sub>5</sub>;25 or R<sup>3</sup> and R<sup>4</sup> together are =O, =S, =NH or =NR<sup>5</sup>;

R<sup>5</sup> represents the same or different groups selected from H, substituted or non-  
 substituted C1 to C10 alkyl, C2 to C10 alkenyl, C2 to C10 alkynyl, substituted or  
 non-substituted C3 to C12 cycloalkyl, substituted or non-substituted benzyl  
 groups, substituted or non-substituted aryl or mono-, bi-, tricyclic unsubstituted or  
 substituted heteroaromatic ring(s) with one or more heteroatoms and non-aromatic  
 heterocycles wherein

the substituents of the substituted groups are selected from C1 to C10 alkyl, C2 to  
 C10 alkenyl, C2 to C10 alkynyl, halogen, substituted or non-substituted aryl, sub-  
 stituted or non-substituted hetero-aromatic compounds, non-aromatic heterocyc-  
 35 cles, C1 to C10 alkyloxy, C1 to C10 alkylamino, C2 to C10 alkenylamino, C2 to C10  
 alkynylamino, COR<sup>6</sup>, CONR<sup>6</sup> and COOR<sup>6</sup>;

R<sup>6</sup> is selected from H, unsubstituted or substituted C1 to C10 alkyl, C2 to C10 al-  
 kenyl or alkynyl, benzyl, aryl, unsubstituted or substituted heteroaromatic rings  
 with one or more hetero-atoms and non-aromatic heterocycles;

40 R<sup>7</sup> and R<sup>8</sup> together form a bridging CH<sub>2</sub>-CH<sub>2</sub> moiety; or

R<sup>7</sup> and R<sup>8</sup> are both hydrogen; as well as pharmaceutically acceptable salts or prod-  
rugs of the compounds of formula (I).

Where cyclic, the alkyl group is preferably C5 to C10, most preferably C5-C7.

- 5 Where acyclic, the alkyl group is preferably C1 to C6, more preferably methyl, ethyl, propyl (n-propyl, isopropyl), butyl (branched or unbranched) or pentyl, and most preferably methyl.

- As used herein, the term "aryl" means an aromatic group, such as phenyl or  
10 naphthyl, or a mono-, bi-, or tricyclic heteroaromatic group containing one or ore heteroatom(s) preferably selected from N, O and S, such as pyridyl, pyrrolyl, quino-  
linyl, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazolyl, tria-  
zolyl, tetrazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrimidinyl, indolyl, pyrazinyl,  
indazolyl, pyrimidinyl, thiophenetyl, pyranyl, carbazolyl, acridinyl, quinolinyl, ben-  
15 zimidazolyl, benzoimidazolyl, benzthiazolyl, purinyl, azapurinyl, cinnolinyl, pter-  
diny.

- As used herein, the term "functional groups" means in the case of unprotected: hy-  
droxy-, thio-, amino-, carboxylic acid and in the case of protected: lower  
20 alkoxy, N-, O-, S- acetyl, carboxylic acid ester.


- As used herein, the term "heteroaryl" means an aromatic group containing one or  
more heteroatom(s) preferably selected from N, O and S, such as pyridyl, pyrrolyl,  
quinolinyl, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazolyl,  
25 triazolyl, imidazolyl, pyrimidinyl, indolyl, pyrazinyl or indazolyl.

- As used herein, the term "non-aromatic heterocycle" means a non-aromatic cyclic  
group containing one or more heteroatom(s) preferably selected from N, O and S,  
such as a cyclic amino group such as pyrrolidinyl, piperidyl, piperazinyl, mor-  
30 pholinyl or a cyclic ether such as tetrahydrofuranyl, monosaccharide.

As used herein the term "halogen" means fluorine, chlorine, bromine or iodine, of  
which chlorine generally is preferred.

As used herein, and unless specified otherwise, the term "substituted" means that the concerned groups are substituted with functional group such as hydroxyl, amine, sulfide, silyl, carboxylic acid, halogen, aryl, etc.

- 5 A presently preferred group of compounds are those represented by the formula II



(II)

wherein:

- 10 R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, hydroxymethyl, or a methylene group linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, or R<sub>1</sub> and R<sub>2</sub> may together represent a double bonded methylene group, and;

- 15 R<sub>3</sub> and R<sub>4</sub> are independently selected from hydrogen, hydroxyl, and benzoyloxy, or R<sub>3</sub> and R<sub>4</sub> may together represent an oxygen atom being double bonded, with the proviso that when either of R<sub>3</sub> and R<sub>4</sub> is a benzoyloxy group, both R<sub>1</sub> and R<sub>2</sub> are hydrogen.

- 20 In the compounds of formula II above, the phenyl group or the nitrogen-containing ring structure of R<sub>1</sub>, and the benzoyloxy group of either of R<sub>3</sub> and R<sub>4</sub> can optionally be substituted, such as for example with halogen, methyl, methoxy, amino and/or halomethyl containing 1-3 halogen atoms.

- 25 A compound of the invention may be in free form, e.g., amphoteric form, or in salt, e.g., acid addition or anionic salt, form. A compound in free form may be converted into a salt form in an art-known manner and vice versa.

- 30 Same compounds are also believed to be capable of inducing apoptosis in angiogenic vascular cells during angiogenesis, thereby inducing regression of angiogenic blood vessels and blocking various disease states dependent on blood vessel forma-

tion and/or vascular cell survival, including the growth and metastasis of various human tumours; adult blindness, e.g. caused by diabetic retinopathy or macular degeneration; psoriasis; states of chronic inflammation, e.g. rheumatoid arthritis; hemangioma; and obesity.

5

In one aspect the present invention provides a method of treating malignant melanoma and/or inhibiting undesired angiogenesis, comprising administering to a mammal in need thereof a pharmaceutically efficient amount of a compound selected from compounds having a structure according to the formula I.

10

The present inventors have also found a previously unknown and most unexpected inactive conformation state of wt p53 protein in tumour cells. The inactive wt p53 conformation has now been found in malignant melanoma cells. More importantly, said inactive wt p53 conformation can be reverted into a functional active conformation, capable of inducing apoptosis. Based on these findings, the present invention, in another aspect, provides a method of testing substances for their ability in transforming inactive wt p53 conformation into an active wt p53 conformation, and thus for finding suitable substances for treating malignant melanoma. The method is defined in claim 6. Since same inactive wt p53 conformation also is believed to be present in angiogenic vascular cells during angiogenesis, same substances are also thought to be useful in inhibiting angiogenesis in pathological conditions known to involve angiogenesis.

15

20

### **Brief description of the attached drawings**

25

FIGURE 1A shows the percentage of apoptotic cells as function of time in human melanoma cells M21 expressing integrin  $\alpha_v\beta_3$  and M21L lacking integrin  $\alpha_v\beta_3$ . FIGURE 1B shows the percentage of apoptotic cells as function of time in human melanoma cells M0, lacking integrin  $\alpha_v\beta_3$ ; M0-2baV, M0 cells overexpressing a chimera of the extracellular domain of the integrin IIb subunit with the cytoplasmic tail of the integrin  $\alpha_v$  subunit; and M0- $\alpha_v$  cells expressing high levels of the integrin  $\alpha_v$  subunit. FIGURE 1C illustrates the cell surface expression of integrin  $\alpha_v\beta_3$  and the integrin  $\beta_3$  subunit in different human melanoma cell lines.

30

FIGURE 1D shows the results of an analysis for cleavage of caspase-8 and caspase-9.

FIGURE 2A; upper panel depicts the specific p53 DNA binding activity in M21 and M21L cells collected from 3D-collagen using an electrophoretic gel shift assay (EMSA) with a p53 supershift using Pab 421; Lower panel presents the protein levels of p53 as compared to actin as a loading control.

FIGURE 2B, same as figure 2A upper panel, but with M0 and M0 $\alpha$ v cells.

FIGURE 2C shows acetylation of p53 at lysine 382 and the protein levels of PUMA, Apaf1, Bax and Bcl-in M21 ( $\alpha$ v+) and M21L ( $\alpha$ v-) cells after culture in 3D-collagen for up to 7 d in 3D collagen were detected by Western blotting.

Data shown in FIGURE 2D represents Pab 1620 and Pab 240 reactivity as percentage of D01 reactivity (total p53) in M21 ( $\alpha$ v $\beta$ 3+) cells and M21L ( $\alpha$ v $\beta$ 3-) cells.

FIGURE 3A upper panel shows the percentage of apoptotic cells in M21 cells ( $\alpha$ v $\beta$ 3+), M21L cells ( $\alpha$ v $\beta$ 3-) and a number of clones of M21L cells ( $\alpha$ v $\beta$ 3-) stably transfected with a dominant negative p53-His175, including M21Lp53His175-0, M21Lp53His175-1, M21Lp53His175-8 and M21Lp53His175-32. Lower panel shows p53 DNA binding activity in these clones after 5 d in 3D collagen.

FIGURE 3B illustrates tumour growth *in vivo* of cells used in Figure 3A.

FIGURE 3C the graph displays values of mean tumour volumes over time out of 5-7 animals for each tumour cell type shown in the Figure.

FIGURE 3D depicts a bar graph showing the tumour wet weights after 25 d of tumour growth in mice of M21, M21L, M21Lp53His175-0 and M21Lp53His175-8.

FIGURE 3E M21 ( $\alpha$ v+), M21L ( $\alpha$ v-) and six individual M21L p53siRNA clones (Lp53siRNA) melanoma cells were cultured in 3D-collagen for the indicated times.

Apoptosis was detected by Annexin-V staining. The blots for p53 and actin protein levels are shown in the vertical display for the cells indicated immediately to the left of each lane. The displayed results are representative among three independent experiments.

FIGURE 4A shows the results of examination of p53 conformation with Pab1620 and Pab240 in M21 and M21L melanoma cells incubated with or without 100  $\mu$ M of PRIMA-1 for 5d.

Figure 4B upper panel shows the results of examination of p53 conformation with Pab 1620 and Pab 240 in AA melanoma cells under 2D culture conditions (d 0) and after 5 d within 3D collagen. Lower panel displays examination of the p53 conformation after 5 d in 3D collagen with or without 100  $\mu$ M PRIMA1.

Figure 4C upper panel shows quantification of apoptosis by Annexin V staining in M21 melanoma cells after 16, 24, 36, and 48 h in 3D collagen with or without treatment with 100  $\mu$ M PRIMA-1. Lower panel shows the results of the same treatment under two-dimensional culture conditions.

FIGURE 4D shows M21 human melanoma tumours grown s.c. in nude mice treated with a single injection of PRIMA-1, lysed and analyzed for acetylation of p53 at lysine 382, phosphorylation of p53 at Ser 15 and the protein levels of PUMA, Apaf1 and by Western blotting 24 and 36 h after PRIMA-1 injection.

FIGURE 4E shows that caspase 9, but not Caspase 8, is activated by PRIMA-1 in M21 melanoma tumors treated as described in Figure 4D.

FIGURE 4F shows that PRIMA-1 induced apoptosis is blocked by the caspase 9 inhibitor Z-LEHD-FMK x TFA (C1355) in 3D-collagen

FIGURE 4G upper panel shows mean tumour volumes over time of M21 human melanoma cells grown in C57/BL nude mice treated with or without PRIMA-1 (100 mg/kg) for 6 d. Lower panel shows mean tumour volumes over time of C8161 human melanoma cells grown in the C57/BL nude mice treated with or without PRIMA-1 (100 mg/kg) for 6 d.

In FIGURE 4H, the tumour wet weights after 25 d of M21 melanoma tumour formation with or without PRIMA-1 treatment as described in Fig. 4G are displayed.

### Detailed description of the invention

p53 is mutated in most human tumours, but the rare p53-mutation frequency in malignant melanoma is puzzling. However, malignant melanoma express high levels of integrin  $\alpha_v\beta_3$ , an integrin that promotes melanoma cell survival (Montgomery et al., *PNAS* 91: 8856-8860 (1994); Petitclerc et al; 1999; Hsu et al., *Am J Pathol.* 153: 1435-1442 (1998)) and suppresses p53-activity in endothelial cells (Strömblad et al., *J. Clin. Invest.* 98:426-433 (1996); Strömblad et al., *J. Biol. Chem.* 277: 13371-13374 (2002)). The present inventors now suggest that integrin  $\alpha_v\beta_3$  suppresses melanoma wt p53-activity via induction of a previously unknown inactive, unfolded wt p53-conformation. In tumor cells, said integrin  $\alpha_v\beta_3$ -regulated p53-activity has been found to govern melanoma cell survival and tumour growth. Dominant negative p53 (His175) as well as p53siRNA was found to restore cell survival and tumor growth of melanoma cells lacking integrin  $\alpha_v\beta_3$ , suggesting that the integrin-mediated inactivation of p53 controls melanoma cell survival. The compound 2,2-



bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one, also referred to as PRIMA-1, previously known from WO0224692 to have the ability to revert mutant p53-conformation to an active state, surprisingly restored the active conformation of wt p53 in melanoma cells, induced apoptosis and blocked melanoma tumor growth in a wt p53-dependent manner. These results may explain the lack of need for p53-mutations in malignant melanoma, and points to a novel principle for melanoma therapy.

Strömblad, S. et al. in *J. Clin. Invest.* 98:426-433 (1996), cited above, the contents of which is incorporated in its entirety herein by reference, reported that proliferative endothelial cells become apoptotic in response to antagonists of integrin  $\alpha_v\beta_3$ , leading to the regression of angiogenic blood vessels, and thereby blocking the growth of various human tumours, and that the blocking of integrin  $\alpha_v\beta_3$  lead to activation of p53.

Based on the findings reported in the above paper, and the findings disclosed in the present application, the inventors also believe the present compounds to be capable of inducing apoptosis in proliferative endothelial cells during angiogenesis, thereby inducing regression of angiogenic blood vessels and blocking various disease states dependent on blood vessel formation and/or vascular cell survival, including the growth and metastasis of various human tumours; adult blindness, e.g. caused by diabetic retinopathy or macular degeneration; psoriasis; states of chronic inflammation, e.g. rheumatoid arthritis; hemangioma; and obesity. Consequently, the same inactive wt p53 conformation as disclosed herein is also believed to be present in such proliferative endothelial cells during angiogenesis.

While the inactive conformation of wt p53 in melanoma cells is believed to be induced by the integrin  $\alpha_v\beta_3$ , the mechanism underlying the induction of any similar inactive wt p53 states in other tissues could be different. However, since the actual mechanism of action of the present compounds is not fully understood, it is also conceivable that the same compounds could be useful for treating other pathological conditions wherein inactive wt p53 is present.

Substances useful in treating other pathological conditions wherein inactive wt p53 is present can be found by means of the generic method of the present invention.

As used herein, the term "inactive wt p53 conformation" is used interchangeably with the term "inactive, unfolded wt p53 conformation" to designate a conformation of wt p53 which is reactive with the monoclonal antibody Pab 240, but does not re-  
5 act with the monoclonal antibody Pab 1620. Furthermore, the inactive conformation also has the ability of being transformed into an active wt p53 conformation by means of the above chemical compound designated PRIMA-1. Inactive wt p53 conformation is further characterized as being incapable of binding to DNA, and incapable of mediating apoptosis.

10 Pab 240 has previously only been known to be reactive with mutant p53 under non-denaturing conditions, while being equally reactive with mutant p53 and wt p53 under denaturing conditions. However, the present inventors have now found Pab 240 also to be reactive to the inactive state of wt p53, defined herein, under  
15 non-denaturing conditions.

Integrin  $\alpha_v\beta_3$  plays a critical role for cutaneous melanoma progression displaying increased expression in the vertically growth phase melanoma lesions compared to more benign radial growth phase lesions (Albeda et al., *Cancer Res.* 50: 6757-6764  
20 (1990)). In experimental models, expression of integrin  $\alpha_v\beta_3$  promotes melanoma cell survival, tumour growth and conversion from radial to the vertical growth phase while blocking of integrin  $\alpha_v\beta_3$  inhibits melanoma tumour growth by inducing apoptosis (Felding-Habermann, *J Clin Invest.* 89: 2018-22 (1992); Petitclerc et al., 1999; Hsu et al., 1998), implicating that integrin  $\alpha_v\beta_3$  functionally regulates melanoma  
25 cell survival. Indeed, integrin  $\alpha_v\beta_3$  has also been found to promote melanoma cell survival in a 3-dimensional environment *in vitro* (Montgomery et al., 1994). But, it is still unclear how integrin  $\alpha_v\beta_3$  can control melanoma cell survival.

The tumour suppressor protein p53 functionally induces apoptotic cell death in response to various types of stresses (Oren, *Cancer Biol.* 5: 221-227 (1994); Ko and Prives, *Genes Dev.* 10: 1054-1072 (1996); Levine, *Cell* 88: 323-331 (1997)). Activated p53 can trigger apoptosis via two pathways (Vousden, *Cell* 103: 691-694 (2000)). One of them is associated with death receptors and activation of caspase-8 (Ashkenazi and Dixit, *Science* 281: 1305-8 (1998)), while the other apoptosis pathway is  
35 mediated through mitochondrial cytochrome c release and subsequent activation of

Apaf1 and caspase-9 (Green and Reed, *Science* 281: 1309-12 (1998)). Furthermore, p53 acts as a specific DNA binding protein to activate or repress expression of a variety of genes, including transcriptionally activating bax (Miyashita et al., *Cell* 80: 293 (1995)), *PIG3* (p53-inducible gene 3, Venot et al., *EMBO J.* 17: 4668-79 (1998)),  
5 *PUMA* (p53 upregulated modulator of apoptosis, Nakano and Vousden, *Mol Cell.* 7: 683-694 (2001)), and Apaf-1 (apoptotic protease-activating factor 1; (Vousden and Lu, 2002)) and transcriptionally repressing bcl-2 (Zhan et al., *Oncogene* 9: 3743-51 (1994)). These downstream targets are functionally involved in certain p53-mediated apoptotic processes.

10 A new mechanism for p53-induced apoptosis acting directly on the mitochondrial membrane has recently been reported by Mihara, A. *et al.* in "p53 has a direct apoptogenic role at the mitochondria", *Molecular Cell*, published 27 January 2003. In accordance therewith, p53, by moving rapidly to the mitochondria, effectively 'jump  
15 starts' and amplifies its slower-starting transcription-dependent effect on apoptosis.

In addition, an antagonist of integrin  $\alpha_v\beta_3$  induces proliferative endothelial cell apoptosis, which is associated with activation of p53 (Strömblad et al., 1996; Strömblad et al., 2002). Although p53 is mutated in most human tumors, wt p53 is dominant  
20 in malignant melanoma (Hollstein et al., 1991; Sparrow et al., 1995; Hartmann et al., 1996). In addition, malignant melanoma are typically refractory to apoptosis induction by chemical drugs or radioactivity.

## Experimental

25 In order to demonstrate that integrin  $\alpha_v\beta_3$ -mediated regulation of p53 regulates melanoma cell survival, the following experimentation, which will be described in more detail hereinafter, was performed. First, M21 human melanoma cells expressing integrin  $\alpha_v\beta_3$ , and the M21L subpopulation lacking integrin  $\alpha_v\beta_3$ , were analyzed  
30 in a 3-dimensional collagen model mimicking the pathophysiological dermal environment. It was found that integrin  $\alpha_v\beta_3$  inhibited p53 activity by inducing an inactive wt p53 conformation. Furthermore, overexpression of a dominant negative p53 mutant (His175) or p53 siRNA restored M21L ( $\alpha_v\beta_3$ -) cell survival and tumour growth, suggesting that p53 is a key target for integrin  $\alpha_v\beta_3$  promoting melanoma  
35 cell survival. Importantly, PRIMA-1 could restore the active conformation of wt p53

in M21 cells and thereby induce melanoma cell apoptosis and suppress melanoma tumour growth. These results reveal a novel principle for treatment of melanoma by reactivation of wt p53.

## 5 Integrin $\alpha_v\beta_3$ promotes melanoma cell survival

With reference to Figure 1A, the maternal human melanoma cells M21, expressing integrin  $\alpha_v\beta_3$ , and a subpopulation, M21L, lacking integrin  $\alpha_v\beta_3$ , were cultured in a three-dimensional collagen gel (3D-collagen). At indicated times, apoptosis was detected by FITC-Annexin-V staining. FACS analysis showed that M21L cells lacking  $\alpha_v\beta_3$  became apoptotic to a much higher degree than M21 cells ( $\alpha_v\beta_3^+$ ), suggesting that integrin  $\alpha_v\beta_3$  expression is critical for melanoma cell survival.

The maternal human melanoma cells M0, lacking integrin  $\alpha_v\beta_3$ ; M0-2baV, M0 cells overexpressing a chimera of the extracellular domain of the integrin IIb subunit with the cytoplasmic tail of the integrin  $\alpha_v$  subunit; and M0- $\alpha_v$  cells expressing high levels of the integrin  $\alpha_v$  subunit, were cultured in a 3D-collagen. At indicated times, apoptosis was examined by FITC-Annexin-V staining. As shown in Figure 1B, FACS analysis showed that M0 $\alpha_v$  cells (expressing  $\alpha_v\beta_3$ ) survived well while both M0 and M02baV cells underwent apoptosis to a higher degree at all time points. This indicates that the integrin  $\alpha_v$ -subunit extracellular ligand binding part is important for melanoma cell survival.

Cell surface expression of integrin  $\alpha_v\beta_3$  and the integrin  $\beta_3$  subunit was analyzed in the human melanoma cell lines M21, M21L, M0, M0- $\alpha_v$  and M0-2baV stained with anti- $\alpha_v\beta_3$  Mab LM609 and anti- $\beta_3$  Mab AP3, respectively. As can be seen from Figure 1C, FACS analysis showed that both  $\alpha_v\beta_3$  and the  $\beta_3$  subunit were expressed in all M21 and M0 $\alpha_v$  cells but rarely expressed in M21L and M0 cells. While integrin  $\beta_3$  was expressed in virtually all M0-2baV cells, integrin  $\alpha_v\beta_3$  was not present.

It has been suggested that unligated integrin  $\alpha_v\beta_3$  might cause apoptosis by direct induction of caspase-8 cleavage (Stupack et al, *J. Cell Biol.* 155: 459-470 (2001)). Therefore, lysates prepared from M21 and M21L cells out of 3D-collagen after 3, 5 and 7 days were analysed by Western blotting for cleavage of caspase-8 and caspase-9. With reference to Figure 1D, no cleavage of caspase-8 in these melanoma

cells was observed, while a control with cycloheximide-treated Jurkate cells displayed caspase-8 cleavage. However, caspase-9 was cleaved to a higher degree in M21L cells ( $\alpha_v\beta_3^-$ ) as compared to M21 ( $\alpha_v\beta_3^+$ ) cells, indicating that lack of integrin  $\alpha_v\beta_3$  caused apoptosis in M21L cells and that this apoptosis might be mediated by a mitochondrial apoptotic pathway involving caspase-9 but did not involve any detectable activation of caspase-8.

### **Integrin $\alpha_v\beta_3$ induces an unfolded conformation of wt p53 and suppresses wt p53 activity**

The specific p53 DNA binding activity was examined in M21 and M21L cells collected from 3D-collagen using an electrophoretic gel shift assay (EMSA) with a p53 supershift using Pab 421. The p53 activity was similar in M21 and M21L cells at day 0. However, as shown in upper panel of Figure 2A, M21L cells lacking integrin  $\alpha_v\beta_3$  displayed an increased p53 activity after culturing in 3D-collagen while M21 cells ( $\alpha_v\beta_3^+$ ) did not.

The protein levels of p53 were analyzed by Western blotting using anti-p53 Pab. With reference to lower panel of Figure 2A, the p53 protein levels in M21 and M21L cells showed no difference within 7 d in 3D-collagen (examination performed on day 0, 3, 5 and 7). The levels of actin were examined as a loading control. This indicates that integrin  $\alpha_v\beta_3$  regulates p53 activity without influencing p53 protein levels.

The specific p53 DNA binding activity was examined in M0 and M0 $\alpha_v$  cells after incubation within 3D-collagen for 5 and 7 days, respectively. The EMSA assay showed that the p53 activity was higher in M0 cells lacking integrin  $\alpha_v\beta_3$  than that in M0 $\alpha_v$  cells ( $\alpha_v\beta_3^+$ ) (see Figure 2B). This verifies the role for integrin  $\alpha_v\beta_3$  regulating melanoma cell p53 activation state in a second cell system.

Acetylation of p53 at lysine 382, a known acetylation site for p53 activation was examined by Western blotting using anti-acetylation p53-L382 pab. As can be seen from Fig. 2C, the levels of acetylated p53 were reduced in M21 cells ( $\alpha_v\beta_3^+$ ) as compared to M21L cells ( $\alpha_v\beta_3^-$ ), while total p53 levels remained the same. Furthermore, PUMA was upregulated in M21L ( $\alpha_v\beta_3^-$ ) cells in parallel with p53 activation, but not

in M21 ( $\alpha_v\beta_3^+$ ) cells, indicating that the p53 activity might transcriptionally activate PUMA.

With reference to Figure 2D, the conformation of p53 was analyzed by ELISA using Pab1620 recognizing the active, folded p53 conformation; Pab 240 recognizing an inactive, unfolded p53 conformation and; DO1 recognizing both folded and unfolded p53 conformations. Data shown in Figure 2D represents Pab 1620 and Pab 240 reactivity as percentage of DO1 reactivity (total p53). It was found that both M21 cells ( $\alpha_v\beta_3^+$ ) and M21L ( $\alpha_v\beta_3^-$ ) displayed an active p53 conformation in regular two-dimensional culture (day 0). However, p53 switched to an inactive unfolded p53 conformation after incubation in 3D-collagen-incubated M21 cells ( $\alpha_v\beta_3^+$ ), while M21L ( $\alpha_v\beta_3^-$ ) maintained an active p53 conformation. This suggests that integrin  $\alpha_v\beta_3$  regulates wt p53 conformation in melanoma cells in a pathophysiological 3-dimensional environment and that the lack of p53-activity in cells expressing integrin  $\alpha_v\beta_3$  is caused by an unfolded, inactive p53-conformation.

#### **Integrin $\alpha_v\beta_3$ -regulated p53 controls melanoma cell survival and melanoma tumor growth**

M21L cells ( $\alpha_v\beta_3^-$ ) were stably transfected with a dominant negative p53-His175 and a number of clones, including M21Lp53His175-0, M21Lp53His175-1, M21Lp53His175-8 and M21Lp53His175-32 were identified by examining p53 activity using EMSA after incubation in 3D-collagen for 5 d. The p53 activity in these clones was reduced to a similar level as in M21 cells expressing  $\alpha_v\beta_3$  (lower panel in Figure 3A). The M21L-p53His175 clones, M21L and M21 cells were incubated within 3D-collagen and apoptosis was examined by FITC-Annexin-V staining at times indicated in Figure 3A. FACS analysis showed that the number of apoptotic cells was lower in the M21L carrying dn p53 clones as compared to M21L, and that the rate of apoptosis in the M21L-dnp53 clones was similar to that in M21 cells expressing integrin  $\alpha_v\beta_3$ , indicating that the over-expression of dominant negative p53 could rescue M21L cells from apoptosis to a similar degree as expression of integrin  $\alpha_v\beta_3$  itself.

Role of integrin-regulated p53 in melanoma tumour growth was investigated *in vivo*. Results are shown in Figure 3B. Melanoma cells ( $1 \times 10^6$ ), including M21L,

M21 and M21L-dn p53 clones M21Lp53His175-0 and M21Lp53His175-8, were injected s.c. into the back of 6-week-old C57/BL nude mice. Each type of injected cell type included 7 mice. The tumours were allowed to grow for 25 d. Tumours were found to be formed by M21Lp53His175-0, M21Lp53His175-8, and M21 cells ( $\alpha_v\beta_3^+$ ), while M21L cells lacking integrin  $\alpha_v\beta_3$  typically did not form tumours within this time.

Tumour volumes were monitored for melanoma growth, as described in the preceding paragraph. Tumour volume over time was determined by the formula: width<sup>2</sup> × length × 0,52. With reference to Figure 3C, the displayed values are mean tumour volumes out of 5-7 animals for each tumour cell type. In the Figure, ♦ represents M21; □ M21L; ▲ Lp53His175-0; and \* Lp53His175-8. M21Lp53His175-0 and M21Lp53His175-8 formed large tumours similar in size to M21 tumours. However, M21L cells lacking integrin  $\alpha_v\beta_3$  typically grew only minimal or developed no tumours.

Bar graph showing the mean values plus minus S.D. tumour wet weights of M21, M21L, M21Lp53His175-0 and M21Lp53His175-8 are contained in Figure 3D. Cells were grown s.c. in nude mice for 25 d as described in Fig 3B.

M21L cells ( $\alpha_v\beta_3^-$ ) were stably transfected with p53-siRNA and a number of clones, including M21Lp53siRNA16, M21Lp53siRNA17, M21Lp53siRNA18, M21Lp53siRNA19, M21Lp53siRNA21, and M21Lp53siRNA22, were identified by examining p53 protein levels using Western blot. (vertical panel in Figure 3E). The M21Lp53siRNA clones, M21L and M21 cells were incubated within 3D-collagen and apoptosis was examined by FITC-Annexin-V staining at times indicated in Figure 3E. FACS analysis showed that the number of apoptotic cells was lower in the M21L carrying dn p53 clones as compared to M21L, and that the rate of apoptosis in the M21L-p53siRNA clones was similar to that in M21 cells expressing integrin  $\alpha_v\beta_3$ , indicating that the over-expression of p53siRNA could rescue M21L cells from apoptosis to a similar degree as expression of integrin  $\alpha_v\beta_3$  itself.

### Example

In this example it will be demonstrated that PRIMA-1 induces an active p53 conformation in integrin  $\alpha_v\beta_3$  positive melanoma cells, induces p53 transcriptional targets, promotes melanoma cell apoptosis, including specific Caspace activation, and suppresses melanoma tumour growth *in vivo*.

5

PRIMA-1 is a substance known from WO0224692 to be able to reactivate the apoptosis-inducing function of mutant p53 proteins. To test if PRIMA-1 could affect also the unfolded, inactive conformation of wt p53 in melanoma cells enforced by integrin  $\alpha_v\beta_3$ , M21 cells ( $\alpha_v\beta_3^+$ ) and M21L cells ( $\alpha_v\beta_3^-$ ) were incubated with or without 100  $\mu$ M PRIMA-1 in 3D-collagen for 7 d. The p53 conformation was examined as described above. The results are presented in Figure 4A. As can be seen, PRIMA-1 could restore active p53 conformation from an unfolded inactive state in M21 cells ( $\alpha_v\beta_3^+$ ), while the p53 conformation in control M21L cells ( $\alpha_v\beta_3^-$ ) was not influenced by PRIMA-1. This demonstrates in an independent way that wt p53 in melanoma cells can undergo conformational changes between unfolded and folded states. More importantly, these results surprisingly indicates that wt p53 unfolded conformation in melanoma cells can be reverted to active conformation by PRIMA-1. To this end, p53 conformation was also analyzed in AA human melanoma cells expressing  $\alpha_v\beta_3$  integrin and wt p53 before and after incubation within 3D collagen (Figure 4B). The results in the upper panel show that p53 in AA cells had an active conformation under 2D culture conditions (day 0) and that incubation within 3D collagen induced an inactive conformation. However, importantly, lower panel shows that treatment of AA melanoma cells with PRIMA-1 enforced p53 into an active conformation within 3D collagen. This shows that PRIMA-1 can be used to convert wt p53 from inactive to an active conformation in different melanoma cells.

Apoptosis was analyzed in M21 cells grown under 2D culture conditions or within 3D-collagen with or without PRIMA-1 treatment for 16, 24, 36 and 48 h. Results are shown in Figure 4C. PRIMA-1 promoted apoptosis in M21 cells ( $\alpha_v\beta_3^+$ ) within 3D collagen to a much higher degree than in 2D culture, suggesting that regulation of the p53 activation state controls melanoma cell survival selectively within 3D environments. This also verifies the results using dn p53 and p53-siRNA (Fig 3) in an independent manner.

30



Figure 4D shows acetylation of p53-Lys382, phosphorylation of p53-Ser15, and protein levels of Apaf-1, PUMA and Bax in M21 human melanoma cell tumors grown in nude mice 24 h and 36 h after a single injection of PRIMA-1, all detected by Western blot. The results show that PRIMA-1 induces p53 acetylation as well as Apaf-1 and PUMA protein levels in melanoma tumors in vivo. Thus, acetylation of p53-Lys382 is potentially involved in p53 activation by PRIMA-1, while Apaf-1 and PUMA are potential downstream mediators of PRIMA-1- and p53-induced melanoma cell apoptosis in vivo.

Figure 4E shows activation of Caspase 9, but not Caspase 8, in M21 human melanoma cell tumors grown in nude mice 24 h and 36 h after a single injection of PRIMA-1, detected by Western blot. The results show that PRIMA-1 induces Caspase 9 is therefore a potential downstream effector of PRIMA-1- and p53-induced apoptosis in melanoma cells in vivo.

Figure 4F shows detection of apoptosis by Annexin-V staining of M21 melanoma cells after 36 h within 3D collagen with or without 80  $\mu$ M of PRIMA-1 with or without the Caspase-9 inhibitor Z-LEHD-FMK x TFA (C1355). The results show that PRIMA-1 induces melanoma cell apoptosis in 3D collagen may be dependent on active Caspase 9 as a downstream mediator.

To test if restoration of an active wt p53 conformation by PRIMA-1 could also induce melanoma cell apoptosis in vivo and thereby block melanoma tumour growth, M21 and C8161 melanoma cells ( $1.5 \times 10^6$ ) were injected s.c. into the back of 6-week-old C57/BL nude mice. The mice were treated with or without PRIMA-1 (100 mg/kg) for 6 d starting 6 d after tumour inoculation. The graph in Figure 4G shows mean tumour volumes calculated as described above for four mice in each group. PRIMA-1 significantly inhibited M21 melanoma growth as compared to PBS control while having no effect on C8161 melanoma growth. Given that C8161 cells have a truncated, unfunctional p53 while M21 cells carry wt p53, the results show that the effect of PRIMA-1 on melanoma growth is dependent on functional p53.

In Figure 4H, the mean of tumour wet weights plus/minus S.D. after 25 d of melanoma tumour formation with or without PRIMA-1 treatment as described in Fig. 4G are displayed. The finding that PRIMA-1 can suppress tumour growth of melanoma

cells carrying wt p53 points to a novel principle for treatment of malignant melanoma by re-activating an inactive conformation of wt p53, which was kept inactive by integrin  $\alpha_v\beta_3$ .

5 Based on these unexpected findings the present inventors also expect structural analogues of PRIMA-1, such as PRIMA-2 and PRIMA-3, which have been described in WO224692, as well as further analogues of PRIMA-1 described in International Patent Application No. PCT/SE03/00206 (not published) to exhibit similar activity as PRIMA-1.

10 Examples of pharmaceutically acceptable addition salts for use in the pharmaceutical compositions of the present invention include those derived from mineral acids, such as hydrochlorid, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, and arylsulphonic acids. The pharmaceutically acceptable excipients described herein, for example, vehicles, adjuvants, carriers or diluents, are well-known to those who are skilled in the art and are readily available. The pharmaceutically acceptable carrier may be one which is chemically inert to the active compounds and which have no detrimental side effects or toxicity under the conditions of use. Pharmaceutical formulations are found e.g. in Remington: The Science and Practice of Pharmacy, 19th ed., Mack Printing Company, Easton, Pennsylvania (1995).


25 The composition according to the invention may be prepared for any route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, or intraperitoneal. The precise nature of the carrier or other material will depend on the route of administration. For a parenteral administration, a parenterally acceptable aqueous solution is employed, which is pyrogen free and has requisite pH, isotonicity, and stability. Those skilled in the art are well able to prepare suitable solutions and numerous methods are described in the literature. A brief review of methods of drug delivery is also found in e.g. Langer, Science 249:1527-1533 (1990).

35 The dose administered to a mammal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the mam-

mal over a reasonable time frame. One skilled in the art will recognize that dosage will depend upon a variety of factors including the potency of the specific compound, the age, condition and body weight of the patient, as well as the stage/severity of the disease. The dose will also be determined by the route (administration form) timing and frequency of administration. In the case of oral administration the dosage can vary from about 0.01 mg to about 1000 mg per day of a compound of formula (I) or the corresponding amount of a pharmaceutically acceptable salt thereof.

- Preferred specific examples of the compounds which can be used according to the present invention are 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one (also referred to as PRIMA-1), 9-(azabicyclo[2.2.2]octan-3-one)-6-chloro-9H-purine (also referred to as PRIMA-2), 2-(hydroxymethyl)quinuclidine-3,3-diol (also referred to as PRIMA-3), 2-(adenine-9-methylene)-3-quinuclidinone, 2-methylene-3-quinuclidinone, 2-(2-amino-3-chloro-5-trifluoromethyl-1-methylaniline)-3-quinuclidinone, 2-(6-trifluoromethyl-4-chlorobenzimidazole-1-methylene)-3-quinuclidinone, 2-(6-methoxypurine-9-methylene)-3-quinuclidinone, 2-(8-azaadenine-9-methylene)-3-quinuclidinone, 1-azabicyclo [2.2.2]oct-3-yl benzoate, 2-(5,6-dimethyl-benzimidazole-1-methylene)-3-quinuclidinone, 2-(8-azaadenine-7-methylene)-3-quinuclidinone, 2-(7-methylene-1,3-dimethyluric acid)-3-quinuclidinone, or 2-(2,6-dichloro-9-methylenepurine)-3-quinuclidinone, or a pharmaceutically acceptable salt thereof.

According to the present invention, A more preferred group of compounds are those having a structure as defined by the following formula III



(III)

wherein

- one of R<sub>1</sub> and R<sub>2</sub> is hydrogen and the other is a methylene group linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and,

more preferably the methylene group is linked to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue.

More preferably, one of R<sub>1</sub> and R<sub>2</sub> in formula II and III is hydrogen, or both R<sub>1</sub> and R<sub>2</sub> are hydroxymethyl groups.

The following compounds are believed to exhibit an activity similar or greater than that of PRIMA-1: 2-(5,6-dimethyl-benzimidazole-1-methylene)-3-quinuclidinone, 2-(8-azaadenine-7-methylene)-3-quinuclidinone, 2-(7-methylene-1,3-dimethyluric acid)-3-quinuclidinone, 2-(2,6-dichloro-9-methylenepurine)-3-quinuclidinone and 2-(6-methoxypurine-9-methylene)-3-quinuclidinone.

**General procedure for testing substances for ability of transferring wild type p53 from its inactive conformation into an active conformation**

15

The inventive methods of testing substances are based on detection of wild type p53 in inactive conformation, either in a direct or indirect manner, as will be explained below.

20 In the methods of the present invention it is essential that only wild type and not mutant p53 is present. Accordingly, in any cells used in the method, only wild type p53 should be expressed, i.e. the p53 gene must not be mutated. Expression of wt p53 can readily be determined by the person skilled in the art using any suitable conventional methods, such as sequencing, mass spectroscopy, DNA-binding tests  
25 etc.

Naturally, it is also essential that the inactive form of wt p53 is present during testing. The presence of the inactive form of wt p53 can then suitably be established in a direct manner by using Pab240.

30

More particularly, the present inventors have found that wt p53 is inactivated under the following conditions: In melanoma cells cultured *in vitro* in a 3-dimensional environment, such as 3D collagen; in melanoma cells in tissue culture after irradiation with UV or gamma radiation, and; in melanoma cells grown *in vivo* in mice. The  
35 inventors also predict that wt p53 will take an inactive conformation in angiogenic

vascular cells during angiogenesis and that the wt p53 inactive conformation is also present in additional cell types and tissues and in other cases can be induced by other means of treatment.

5 The method of monitoring any changes in the level of inactive wt p53 during testing is not critical according to the invention, as long as the method allows for detection of any substantial reduction in the level inactive wt p53 and a consequent induction of active p53 levels.

10 Based upon the above definition of the new inactive wt p53 state, and the present detailed description, the skilled person will be able to find suitable methods for detecting and/or monitoring the level of inactive wt p53 using common general knowledge. Such methods will generally be based on measurement of wt p53 conformation and/or activity state, as will be explained below in further detail.

15 During testing, the level of inactive wt p53 can for example be established by using a suitable conformational-specific antibody, recognising only the inactive form, such as the above-mentioned Pab240. Since the total cellular level of wt p53 is formed by the combined levels of inactive p53 and active p53, respectively, measurement of the active p53 conformation can also be used as an indirect measurement of inactive p53, i.e. an absence of active p53 indicates that p53 is instead inactive. Measurement of the active p53 conformation can also be performed using a suitable conformational-specific antibody, such as Pab 1620. If desired, the total level of wt p53 can be measured by means of a suitable antibody, which does not discriminate between the inactive and active forms of wt p53, such as DO1.

Of course, other direct or indirect parameters reflecting the activity state of wt p53 could also be used. Accordingly, the activity state of wt p53 can for example be detected by measurement of p53-binding to DNA, by absence of expression of reporter constructs, for example using GFP or luciferase as reporters, by measurement of p53 target genes, as indicated in Figures 2C and 4D, e.g. PUMA-1, Apaf-1, PIG-3, GADD45, Mdm2, p21-CIP1, bax, bcl-2, and/or caspase-3, by using microarray-related techniques to analyse specific p53 target genes or gene expression patterns indicating p53 activity and/or by measuring the capability of wt p53 to induce apoptosis and/or growth arrest and/or the activity of molecules involved in these

pathways upstream or downstream of p53, e.g. activation of caspase 9 and caspase 3 as indicated in Figure 4E.

Also, as indicated in Fig 2C and 4D, specific p53 acetylation could also be used as an indication of p53 activity. Likewise, phosphorylation of p53 is also conceivable as an indication of p53 activity.

The use of antibodies is however presently preferred for being a practical and more direct method of detecting and monitoring inactive wt p53, especially when Pab240 is used.

The general method of testing substances for the ability of transferring wt p53 from an inactive conformation into an active conformation according to the present invention will thus include the following general steps:

- A. Providing cells carrying wt p53 wherein inactive wt p53 conformation is present;
- B. Exposing the cells to a substance to be tested; and
- C. Measuring the cellular level of inactive wt p53 conformation, for example by any of the above-mentioned methods.

The above general method can be adapted to both *in vitro* or *in vivo* testing by exposing the cells in step B either *in vivo* or *in vitro* to the substance to be tested, as will be readily understood hereinafter.

Step C is typically performed both before and after exposing the cell in step B to a substance to be tested.

***In vitro* testing of substances for ability of transferring wild type p53 from its inactive conformation into an active conformation**

In the case of *in vitro* testing for substances capable of reverting an inactive p53 conformation to an active conformation, cells carrying wt p53 can be grown in a 3-dimensional environment and the conformation and/or activity state of p53 measured, for example by any of the methods mentioned above, with and without, respectively, the addition of a substance for testing. A substance is considered func-

tional if it is found to be capable of changing the conformation and/or activity of inactive wt p53. Alternatively, cells with wt p53 could be irradiated in order to induce the inactive wt p53 conformation, exposed to a substance to be tested, and thereafter analysed for p53 conformation and/or activity. Alternatively, a cell naturally displaying an inactive wt p53 conformation could be utilized or an inactive wt p53 conformation could be induced by other means, the cell thereafter being exposed to a substance to be tested, and analysed for inactive p53 state.

A tissue, an organ, or a part thereof, from a human or from an animal could also be cultured, treated and used for the inventive testing as described for cells *in vitro* above. Although such models sometimes are referred to as *ex-vivo* models, when used in the inventive method of testing of substances herein, such method is considered to be a method of *in-vitro* testing.

Alternatively, *in-vitro* testing of substances could be performed in models of angiogenesis. In vitro examples include, but are not limited to, tube forming assays of endothelial cells, outgrowth of blood vessels from stem cells, outgrowth of blood vessels from an isolated vessel originating from an animal or human, or analysis of endothelial cells in tissue culture.

An *in-vitro* testing procedure could thus for example include the following general steps:

- A. Providing cells carrying wt p53 *in vitro*, and inducing inactive wt p53 conformation if not already present;
- B. Exposing the cells to a substance to be tested; and
- C. Measuring the cellular level of inactive wt p53 conformation, directly or indirectly for example by any of the above-mentioned methods.

Step C is typically performed both before and after exposing the cell in step B to a substance to be tested.

***In vivo* testing of substances for ability of transferring wild type p53 from its inactive conformation into an active conformation**

Likewise, wt p53 conformation and/or activity could be assessed *in vivo*. For example, melanoma cells xenografts could be used *in vivo* to test substances for their capacity of reverting an inactive p53 conformation to active p53. In this case, an animal carrying such tumour xenograft would be treated with a substance to be tested, and the effect of this substance on wt p53 conformation and activity measured as described above. Alternatively, testing of substances could be carried out in animal melanoma models, where melanoma is occurring naturally or is provoked within the animal by treatment e.g. by UV-radiation and/or by carcinogenic chemicals and/or by genetic modifications. Administration of test substance to the animal can be performed i.v., i.p., s.c., intratumoural, or otherwise.

Alternatively, *in-vivo* testing of substances could be performed in models of angiogenesis. Examples of *in-vivo* models include, but are not limited to, stimulation of angiogenesis in the chick embryo chorioallantoic membrane, stimulation of angiogenesis by a transplant of extracellular matrix or comparable substances onto mice or onto another animal, stimulation of angiogenesis in the cornea by an angiogenic compound, stimulation of angiogenesis in the retina by hypoxia, analysis of developmental angiogenesis in the retina or elsewhere, and induction of angiogenesis by a tumour xenograft or another type of xenograft. Measurement of angiogenesis is performed by a quantification of the number of blood vessels within the tissue and/or by quantification of vascular cell markers and/or by measurement of vascular cell apoptosis and/or of vascular cell proliferation and/or by similar means.

An *in-vivo* testing procedure could for example comprise the following general steps:

- A. Providing an animal expressing wt p53 in a tissue thereof, wherein inactive wt p53 conformation is present;
- B. Exposing cells of the tissue of the animal *in vivo* to a substance to be tested; and
- C. Measuring the cellular level of inactive wt p53 conformation, directly or indirectly, for example by any of the above-mentioned methods.

Step C is typically performed both before and after exposing the cell in step B to a substance to be tested.




Alternatively, and as illustrated in Figure 4G positive testing of a compound can also be established by comparing the effect of the tested substance in cells or tissues carrying functional p53 to the effect on cells or tissues with no or non-functional p53. Obviously, the observable effect can for example relate to a reduced tumour volume or weight, or number of tumour cells or induction of apoptosis or indications thereof, e.g. as described in Figure 4. Accordingly, in the above *in vivo* and *in vitro* methods, instead of step C, an alternative step C' can be used comprising comparing the effect of the tested substance on the cells or tissue (carrying functional p53) in step B to the effect on cells or tissues with no or non-functional p53.

Alternatively, testing of a compound can also be tested by comparing the effect of the tested substance on other physiological or pathological mechanisms where wt p53 conformation could play an active role for the regulation, e.g. in angiogenesis as motivated above. In such cases, the observable effects could be the effect of the tested substance on the particular physiological or pathological events, e.g. the amount of newly formed blood vessels formed by angiogenesis and/or the amount of apoptosis or indications thereof in vascular cells.

The animals are typically sacrificed after the above-described *in-vivo* testing of substances.

**Claims**

1. Use of a compound capable of transferring wild type p53 from an inactive con-  
formation thereof, which conformation is reactive to Pab 240 and not to Pab 1620,  
5 into an active conformation capable of inducing apoptosis, which compound is se-  
lected from compounds having a structure according to the formula I



20 wherein

n is 0, 1 or 2;

R<sup>1</sup> and R<sup>2</sup> are the same or different and are selected from -H, -CH<sub>2</sub>-R<sup>5</sup>, -CH<sub>2</sub>-O-R<sup>5</sup>,

-CH<sub>2</sub>-S-R<sup>5</sup>, -CH<sub>2</sub>-NH-R<sup>5</sup>, -CO-O-R<sup>5</sup>, -CO-NH-R<sup>5</sup>, -CH<sub>2</sub>-NH-CO-R<sup>5</sup>,

25 -CH<sub>2</sub>-O-CO-R<sup>5</sup>, -CH<sub>2</sub>-NH-CO-NHR<sup>5</sup>, -CH<sub>2</sub>-NH-CO-OR<sup>5</sup>, -CH<sub>2</sub>-NH-CS-NHR<sup>5</sup> and  
-CH<sub>2</sub>-O-CO-NHR<sup>5</sup>; or R<sup>1</sup> and R<sup>2</sup> are together =CH<sub>2</sub>;

R<sup>3</sup> and R<sup>4</sup> are the same or different and are selected from -H, -OH, -SH, -NH<sub>2</sub>, -NHR<sup>5</sup> and -O-CO-C<sub>6</sub>H<sub>5</sub>; or R<sup>3</sup> and R<sup>4</sup> together are =O, =S, =NH or =NR<sup>5</sup>;


R<sup>5</sup> represents the same or different groups selected from H, substituted or  
30 non-substituted C1 to C10 alkyl, C2 to C10 alkenyl, C2 to C10 alkynyl, substituted  
or non-substituted C3 to C12 cycloalkyl, substituted or non-substituted benzyl  
groups, substituted or non-substituted aryl or mono-, bi-, tricyclic unsubstituted or  
substituted heteroaromatic ring(s) with one or more heteroatoms and non-aromatic  
heterocycles wherein

35 the substituents of the substituted groups are selected from C1 to C10 alkyl, C2 to  
C10 alkenyl, C2 to C10 alkynyl, halogen, substituted or non-substituted aryl, sub-  
stituted or non-substituted hetero-aromatic compounds, non-aromatic heterocy-  
cles, C1 to C10 alkyloxy, C1 to C10 alkylamino, C2 to C10 alkenylamino, C2 to C10  
alkynylamino, COR<sup>6</sup>, CONR<sup>6</sup> and COOR<sup>6</sup>;

R<sup>6</sup> is selected from H, unsubstituted or substituted C1 to C10 alkyl, C2 to C10 alkenyl or alkynyl, benzyl, aryl, unsubstituted or substituted heteroaromatic rings with one or more hetero-atoms and non-aromatic heterocycles;

R<sup>7</sup> and R<sup>8</sup> together form a bridging CH<sub>2</sub>-CH<sub>2</sub> moiety; or R<sup>7</sup> and R<sup>8</sup> are both hydrogen;  
 or a pharmaceutically acceptable salt or prodrug thereof,  
 for the preparation of a medicament for use in treating malignant melanoma and/or a pathological condition involving undesired angiogenesis.

2. The use of claim 1, wherein the compound is selected from compounds having the following formula (II)



(II)

wherein:

R<sub>1</sub> and R<sub>2</sub> are independently selected from hydrogen, hydroxymethyl, or a methylene group linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, or R<sub>1</sub> and R<sub>2</sub> may together represent a double bonded methylene group, and;


R<sub>3</sub> and R<sub>4</sub> are independently selected from hydrogen, hydroxyl, and benzoyloxy, or R<sub>3</sub> and R<sub>4</sub> may together represent an oxygen atom being double bonded, with the proviso that when either of R<sub>3</sub> and R<sub>4</sub> is a benzoyloxy group, both R<sub>1</sub> and R<sub>2</sub> are hydrogen, or a pharmaceutically acceptable salt or prodrug thereof.

3. The use of claim 2, wherein the compound is selected from 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one, 9-(azabicyclo[2.2.2]octan-3-one)-6-chloro-9H-purine, 2-(hydroxymethyl)quinuclidine-3,3-diol, 2-(adenine-9-methylene)-3-quinuclidinone, 2-methylene-3-quinuclidinone, 2-(-2-amino-3-chloro-5-trifluoromethyl-1-methylaniline)-3-quinuclidinone, 2-(6-trifluoromethyl-4-chlorobenzimidazole-1-methylene)-3-quinuclidinone, 2-(6-methoxypurine-9-

methylene)-3-quinuclidinone, 2-(8-azaadenine-9-methylene)-3-quinuclidinone, 1-azabicyclo [2.2.2]oct-3-yl benzoate, 2-(5,6-dimethyl-benzimidazole-1-methylene)-3-quinuclidinone, 2-(8-azaadenine-7-methylene)-3-quinuclidinone, 2-(7-methylene-1,3-dimethyluric acid)-3-quinuclidinone, or 2-(2,6-dichloro-9-methylenepurine)-3-quinuclidinone, or a pharmaceutically acceptable salt thereof.

4. The use of anyone of the claims 1-3 together with a pharmaceutically acceptable carrier, diluent and/or excipient.

5. A method of treating malignant melanoma and/or inhibiting undesired angiogenesis, comprising administering to a mammal in need thereof a pharmaceutically efficient amount of a compound selected from compounds having a structure according to the formula I



wherein

n is 0, 1 or 2;

R<sup>1</sup> and R<sup>2</sup> are the same or different and are selected from -H, -CH<sub>2</sub>-R<sup>5</sup>, -CH<sub>2</sub>-O-R<sup>5</sup>, -CH<sub>2</sub>-S-R<sup>5</sup>, -CH<sub>2</sub>-NH-R<sup>5</sup>, -CO-O-R<sup>5</sup>, -CO-NH-R<sup>5</sup>, -CH<sub>2</sub>-NH-CO-R<sup>5</sup>, -CH<sub>2</sub>-O-CO-R<sup>5</sup>, -CH<sub>2</sub>-NH-CO-NHR<sup>5</sup>, -CH<sub>2</sub>-NH-CO-OR<sup>5</sup>, -CH<sub>2</sub>-NH-CS-NHR<sup>5</sup> and -CH<sub>2</sub>-O-CO-NHR<sup>5</sup>; or R<sup>1</sup> and R<sup>2</sup> are together =CH<sub>2</sub>;

R<sup>3</sup> and R<sup>4</sup> are the same or different and are selected from -H, -OH, -SH, -NH<sub>2</sub>, -NHR<sup>5</sup> and -O-CO-C<sub>6</sub>H<sub>5</sub>; or R<sup>3</sup> and R<sup>4</sup> together are =O, =S, =NH or =NR<sup>5</sup>;

R<sup>5</sup> represents the same or different groups selected from H, substituted or non-substituted C1 to C10 alkyl, C2 to C10 alkenyl, C2 to C10 alkynyl, substituted or non-substituted C3 to C12 cycloalkyl, substituted or non-substituted benzyl groups, substituted or non-substituted aryl or mono-, bi-, tricyclic unsubstituted or substituted heteroaromatic ring(s) with one or more heteroatoms and non-aromatic heterocycles wherein

the substituents of the substituted groups are selected from C1 to C10 alkyl, C2 to C10 alkenyl, C2 to C10 alkynyl, halogen, substituted or non-substituted aryl, substituted or non-substituted hetero-aromatic compounds, non-aromatic heterocycles, C1 to C10 alkyloxy, C1 to C10 alkylamino, C2 to C10 alkenylamino, C2 to C10 alkynylamino, COR<sup>6</sup>, CONR<sup>6</sup> and COOR<sup>6</sup>;

R<sup>6</sup> is selected from H, unsubstituted or substituted C1 to C10 alkyl, C2 to C10 alkenyl or alkynyl, benzyl, aryl, unsubstituted or substituted heteroaromatic rings with one or more hetero-atoms and non-aromatic heterocycles;

R<sup>7</sup> and R<sup>8</sup> together form a bridging CH<sub>2</sub>-CH<sub>2</sub> moiety; or R<sup>7</sup> and R<sup>8</sup> are both hydrogen; or a pharmaceutically acceptable salt or prodrug thereof.

6. Method of testing compounds for the ability of transferring wild type p53 from an inactive conformation into an active conformation comprising the steps:

- A. Providing cells carrying wt p53, in which cells inactive wt p53 conformation is present;
- B. Exposing the cells *in vitro* to a substance to be tested; and
- C. Measuring the cellular inactive wt p53 conformation.

7. The method of claim 6, wherein instead of step C an alternative step C' is used comprising comparing the effect of the tested substance on the cells (carrying functional p53) in step B to the effect on cells or tissues with no or non-functional p53.

8. The method of claim 6 or 7, wherein integrin  $\alpha_v\beta_3$  is present in the cells.

9. The method of claim 6-8, wherein the Pab 240 is used for detecting wt p53 in its inactive conformation.

10. The method of any of the claims 6-9, wherein a compound of claim 1 is tested.

11. The method of any of the claims 6-10, wherein the cells in step B are exposed *in vivo* in an animal to the substance to be tested, and the animal subsequently sacrificed.

Figure 1A




Figure 1B




Figure 1C  
Upper panel




Figure 1C  
Lower panel






Figure 1D




Figure 2A




Figure 2B




Figure 2C




Figure 2D







Figure 3A



**Figure 3B**




Figure 3C




Figure 3D




Figure 3E






Figure 4A




Figure 4B






Figure 4C



+ PRIMA1  
- PRIMA1

Figure 4D




Figure 4E




Figure 4F




Figure 4 G






Figure 4H



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/000452

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/439, A61K 31/52, A61K 31/4015, A61P 35/00  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM. ABS DATA, BIOSIS, EMBASE, MEDLINE, EPO-INTERNAL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 0224692 A1 (KAROLINSKA INNOVATIONS AB), 28 March 2002 (28.03.2002) --	1-11
A	J. Clin. Invest., Vol. 98, no. 2, July 1996, Staffan Strömblad et al: "Suppression of p53 Activity and p21WAF1/CIP1 Expression by Vascular Cell Integrin alpha v beta 3 during Angiogenesis", page 426 - page 433 --	1-11
A	The Journal of Biological Chemistry, Vol. 277, no. 16, 19 April 2002, Staffan Strömblad et al: "Loss of p53 Compensates for alpha v-Integrin Function in Retinal Neovascularization", page 13371 - page 13374 --	1-11

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 June 2004

Date of mailing of the international search report

02-07-2004

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Per Renström/BS

Telephone No. +46 8 782 25 00

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/000452

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Carcinogenesis, Vol. 23, no. 12, 2002, Vladimir J.N. Bykov et al: "Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database", page 2011 - page 2018</p> <p>--</p>	1-11
A	<p>Nature Medicine, Vol. 8, no. 3, March 2002, Vladimir J.N. Bykov et al: "Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound", page 282 - page 288</p> <p>--</p>	1-11
P,X	<p>WO 03070250 A1 (KAROLINSKA INNOVATIONS AB), 28 August 2003 (28.08.2003)</p> <p>--</p> <p>-----</p>	1-11



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE 2004/000452

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 5  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see extra sheet**
2. ☒ Claims Nos.: 1, 4-5  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
**see extra sheet**
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## Box II.1

Claim 5 relates to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds or compositions.

## Box II.2

Present claims 1 and 4-5 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds for which pharmaceutical use is claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts related to the compounds in claims 2-3, except for the parts related to the expression "prodrug" (see below).

The scope of claims 1-2 and 4-5, as far as the expression "prodrug" is concerned, is so unclear (Article 6 PCT) that a meaningful search is impossible with regard to this expression.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

30/04/2004

International application No.

PCT/SE 2004/000452

WO	0224692	A1	28/03/2002	AU	9042201	A	02/04/2002
				CA	2423192	A	28/03/2002
				EP	1319000	A	18/06/2003
				US	2003166674	A	04/09/2003
-----							
WO	03070250	A1	28/08/2003	EP	1377334	A	07/01/2004
				SE	0200523	D	00/00/0000
-----							